Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

Costa, Ricardo L. B., Han, Hyo Sook, Gradishar, William J. · 2018 · Breast Cancer Research and Treatment

Abstract

Purpose Triple-negative breast cancer (TNBC) accounts for approximately 20% of breast cancer cases. Although there have been advances in the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancers, targeted therapies for TNBC remain unavailable. In this narrative review, we summarize recent discoveries related to the underlying biology of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway in TNBC, examine clinical progress to date, and suggest rational future approaches for investigational therapies in TNBC.Results As with other subtypes of breast cancer, aberrations in the PI3K/AKT/mTOR pathway are common in TNBC. Preclinical data support the notion that these aberrations predict TNBC inhibition by targeted agents. In a recently published phase 2 clinical trial, an AKT inhibitor (ipatasertib) improved outcomes in a subset of patients with metastatic TNBC when combined with paclitaxel in the first-line setting. In addition, new compounds with distinct specificity and potency targeting different PI3K/AKT/mTOR components and cognate molecules (e.g., mitogen-activated protein kinase) are being developed. These agents present a wide range of toxicity profiles and early efficacy signals, which must be considered prior to the advancement of new agents in later-phase clinical trials.Conclusions The development of drugs targeting the PI3K/AKT/mTOR pathway for the treatment of TNBC is an evolving field that should take into account the efficacies and toxicities of new agents in addition to their interactions with different cancer pathways.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10549-018-4697-y

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 73 references

Cited by

See all 456

Metadata

Authors
Costa, R. L. B., Han, H. S., & Gradishar, W. J.
Affiliations
  • Moffitt Cancer Center (US)
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University (US)
Corresponding author
Costa, Ricardo L. B.
Venue
Breast Cancer Research and Treatment
Published
2018-02-07
Volume
169
Issue
3
Pages
397-406
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
OpenAlex
W2786784128
Cited by
439
References
73
Citations by year
2026: 19 · 2025: 38 · 2024: 37 · 2023: 77 · 2022: 65 · 2021: 67 · 2020: 68 · 2019: 47 · 2018: 20
FWCI
4.97
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
triple-negative breast cancer, PI3K/AKT/mTOR pathway, targeted therapy, ipatasertib, AKT inhibitors, mTOR inhibitors, PI3K inhibitors, MAPK inhibitors, paclitaxel, metastatic breast cancer, drug toxicity, drug interactions
MeSH terms
Animals, Female, Humans, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases, Molecular Targeted Therapy, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. https://app.cochat.ai/papers/10.1007/s10549-018-4697-y
The paper
Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018). Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-018-4697-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.